|
| Press Releases |
|
 |
|
| Friday, March 24, 2023 |
|
|
医思健康与诺辉健康达成战略合作 共同推动「宫证清」在港上市 |
| 医思健康（2138.HK）与诺辉健康（6606.HK）今日举行签约仪式，双方达成独家战略合作，未来将全面整合双方的优质资源，共同推动宫证清在中国香港的注册上市、分销及市场推广，以居家早筛助力宫颈癌预防医学服务的普及，加速实现宫颈癌的有效预防。 more info >> |
|
|
醫思健康與諾輝健康達成戰略合作 共同推動「宮證清」在港上市 |
| 醫思健康（2138.HK）與諾輝健康（6606.HK）今日舉行簽約儀式，雙方達成獨家戰略合作，未來將全面整合雙方的優質資源，共同推動宮證清在中國香港的註冊上市、分銷及市場推廣，以居家早篩助力宮頸癌預防醫學服務的普及，加速實現宮頸癌的有效預防。 more info >> |
|
|
EC Healthcare Collaborates with New Horizon Health to form Strategic Partnership To Jointly Launch CerviClear in Hong Kong |
| EC Healthcare (2138.HK) and New Horizon Health (6606.HK) host ceremony today to form an exclusive strategic partnership. Both parties will consolidate the resources to empower the launching, distribution, and promotion of CerviClear in Hong Kong. more info >> |
|
| Friday, August 19, 2022 |
|
|
New Horizon Health Announced 2022 Interim Report: Revenue Up 414% YoY, Gross Margin Climbs to 82% |
New Horizon Health (6606.HK), China's leading biotechnology company for early cancer screening, announced its half-year results for the year ended June 30, 2022 today.
more info >> |
|
| Friday, March 18, 2022 |
|
|
诺辉健康发布2021年报：营收同比增长202%，毛利率攀升至72.7% |
| 中国领先的癌症早筛生物高科技公司诺辉健康（6606.HK）今日发布2021年截至12月31日的年度业绩报告。 more info >> |
|
|
諾輝健康發佈2021年報：營收同比增長202%，毛利率攀升至72.7% |
| 中國領先的癌症早篩生物高科技公司諾輝健康（6606.HK）今日發佈2021年截至12月31日的年度業績報告。 more info >> |
|
| Saturday, August 21, 2021 |
|
|
New Horizon Health Announces 2021 Interim Results: Revenue Increases 317% Year-on-year, Gross Profit Margin Climbs to 56.2% |
| New Horizon Health (6606.HK) (the "Company"), the first public listed cancer screening company in China, has today announced its financial report for the first half year ended 30 June 2021. more info >> |
|
| Friday, August 20, 2021 |
|
|
諾輝健康發佈2021年中報業績：營收同比增長317%，毛利率攀升至56.2% |
| 中國首家專注於癌症早篩的生物高科技公司諾輝健康（6606.HK）今日發佈2021年上半年截至6月30日的財務報告。 more info >> |
|
| Monday, February 8, 2021 |
|
|
基因检测行业的未来明珠获资本巨头鼎力相助 诺辉健康潜力十足 |
| 开年至今，港股市场氛围热烈，康希诺生物、荣昌生物、康方生物等生物科技公司涨势喜人。由于新冠肺炎疫情仍在世界范围扩散，促使医疗需求急剧上升，此类生物科技领域的「18A上市公司」自2020年以来愈发受到市场关注，股价表现亮眼。 more info >> |
|
|
基因檢測行業的未來明珠獲資本巨頭鼎力相助 諾輝健康潛力十足 |
| 開年至今，港股市場氛圍熱烈，康希諾生物、榮昌生物、康方生物等生物科技公司漲勢喜人。由於新冠肺炎疫情仍在世界範圍擴散，促使醫療需求急劇上升，此類生物科技領域的「18A上市公司」自2020年以來愈發受到市場關注，股價表現亮眼。 more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
XCF Global and Continual Renewable Ventures Announce Memorandum of Understanding to Launch New Rise Australia, a SAF and HVO Platform Powered by XCF
Jun 26, 2025 09:30 HKT/SGT
|
|
|
穩定幣條例下的隱形巨頭：百仕達的真實價值
Jun 26, 2025 09:03 HKT/SGT
|
|
|
稳定币条例下的隐形巨头：百仕达的真实价值
Jun 26, 2025 08:59 HKT/SGT
|
|
|
港股「香水第一股」穎通控股（06883）今日正式掛牌
Jun 26, 2025 07:05 HKT/SGT
|
|
|
港股“香水第一股”颖通控股（06883）今日正式挂牌
Jun 26, 2025 07:02 HKT/SGT
|
|
|
Investing News Network Strengthens Australian Presence with Appointment of Industry Veteran John Phillips
Jun 26, 2025 00:39 HKT/SGT
|
|
|
Silo Pharma Enters into Letter of Intent for JV with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market
Jun 25, 2025 22:27: JST
|
|
|
交易寶2025年5月亮相HOFEX 2025及HK Tech 300 Expo 助力商戶數碼轉型
Jun 25, 2025 22:21 HKT/SGT
|
|
|
PCG Showcases at HOFEX 2025 and HK Tech 300 Expo in May 2025, Driving Digital Transformation for Merchants
Jun 25, 2025 22:17 HKT/SGT
|
|
|
Silo Pharma Enters Letter of Intent for JV with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market
Jun 25, 2025 22:27 JST
|
|
|
Galaxy Payroll Partners with CURRENC to Integrate AI and Stablecoin Technology in HR Solutions
Jun 25, 2025 20:30 HKT/SGT
|
|
|
China Medical System Holdings Limited: Proposed Secondary Listing on the Singapore Exchange
Jun 25, 2025 19:00: JST
|
|
|
康哲藥業建議於新加坡交易所第二上市
Jun 25, 2025 18:13 HKT/SGT
|
|
|
China Medical System Holdings Limited: Proposed Secondary Listing on the Singapore Exchange
Jun 25, 2025 18:00 HKT/SGT
|
|
|
從技術先驅到全球AMR第一 極智嘉商業化領跑行業
Jun 25, 2025 17:45 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
